Lean Ozempic when…
- Cardiovascular risk reduction is a priority — the semaglutide molecule has CV outcome trials
- Longer real-world experience matters to you
- Your insurance favors Ozempic
HEAD TO HEAD
Ozempic vs Mounjaro.
Ozempic (semaglutide) and Mounjaro (tirzepatide) are both weekly injectables FDA-approved for type 2 diabetes. Mounjaro showed stronger A1C and weight results head-to-head against semaglutide 1 mg (SURPASS-2); Ozempic has the longer safety track record and dedicated cardiovascular outcome data (SUSTAIN-6, SELECT for the molecule). Your clinician chooses based on your clinical picture, tolerance, and coverage — GLP AI tracks either.
Education only, from FDA labels and published trials — never medical advice. Which medication is right for you is a decision for you and your clinician.
VERIFIEDGLP AIOzempic vs MounjaroSources verified July 15, 2026
1M+Downloads across iOS, Android & web
4.9★App Store rating
iPhone + AndroidApp Store + Google Play
Either oneGLP AI tracks both — shots or pills
FDA-labeledFacts from prescribing information, cited
One timelineDoses · meals · symptoms · levels
AT A GLANCE
When each one makes sense.
Lean Mounjaro when…
- Greater average A1C and weight reduction in head-to-head data matters (SURPASS-2)
- You plateaued on or didn't tolerate semaglutide
- Your clinician wants the dual GIP/GLP-1 mechanism
These are talking points for a clinician conversation, not a prescription.
SIDE BY SIDE
Ozempic vs Mounjaro, feature by feature.
| Ozempic | Mounjaro | |
|---|---|---|
| Active ingredient | semaglutide | tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approval | FDA-approved for type 2 diabetes | FDA-approved for type 2 diabetes |
| Form & frequency | Injection, weekly | Injection, weekly |
| Dose range | 0.25 mg → 2.0 mg | 2.5 mg → 15 mg |
| Half-life | ~7 days | ~5 days |
| Headline trial result | Semaglutide reduced major cardiovascular events by 26% in SUSTAIN-6 (type 2 diabetes) | A1C reductions of 1.87–2.07% as monotherapy in SURPASS-1; superior A1C reduction vs semaglutide 1 mg in SURPASS-2 |
| Most common side effect | Nausea (15.8–20.3%) | Nausea (12–18%) |
| Tracked by GLP AI | ✅ Doses, meals, side effects, levels | ✅ Doses, meals, side effects, levels |
Sources: Ozempic Prescribing Information (Novo Nordisk) · Mounjaro Prescribing Information (Eli Lilly) · trials as cited on each medication's page.
WHICHEVER YOU CHOOSE
Track either with GLP AI.
Doses (shots or pills), a 0–100 GLP-1 Meal Score for every meal, side effects beside dose days, and an estimated medication level chart — the journey looks the same in GLP AI no matter which medication you and your clinician pick.
THE QUICK ANSWERS
Ozempic vs Mounjaro — FAQs.
What is the difference between Ozempic and Mounjaro?+
Ozempic (semaglutide) and Mounjaro (tirzepatide) are both weekly injectables FDA-approved for type 2 diabetes. Mounjaro showed stronger A1C and weight results head-to-head against semaglutide 1 mg (SURPASS-2); Ozempic has the longer safety track record and dedicated cardiovascular outcome data (SUSTAIN-6, SELECT for the molecule). Your clinician chooses based on your clinical picture, tolerance, and coverage — GLP AI tracks either.
How are Ozempic and Mounjaro dosed?+
Ozempic: 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg, weekly (injection). Mounjaro: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, weekly (injection). Escalation schedules come from each FDA label; your prescriber sets the pace.
How long do Ozempic and Mounjaro stay in your system?+
Ozempic (semaglutide) has a ~7 days half-life; Mounjaro (tirzepatide) has a ~5 days half-life. That difference shapes dosing frequency and how missed doses feel — GLP AI's medication level chart visualizes both.
Which has more side effects — Ozempic or Mounjaro?+
Both are GI-first. Ozempic's label lists nausea at 15.8–20.3%; Mounjaro's lists nausea at 12–18%. Cross-trial numbers aren't directly comparable, and individual tolerance varies — tracking your own timeline is more useful than comparing labels.
Can I switch between Ozempic and Mounjaro?+
Switching between GLP-1 medications is common and is entirely a decision for your prescriber, who will map an equivalent starting dose. A tracked history — doses, side effects, weight — makes that conversation concrete.
Which is right for me — Ozempic or Mounjaro?+
That's a clinical decision based on your health history, goals, tolerance, and coverage. This page is education, not medical advice. Whichever you and your clinician choose, GLP AI tracks it.
How do I track Ozempic or Mounjaro?+
GLP AI tracks both: doses (shots or pills), a 0–100 GLP-1 Meal Score for every meal, side effects beside dose days, and an estimated medication level chart — one timeline either way.
Did Ozempic and Mounjaro ever go head-to-head?+
Yes — SURPASS-2 compared tirzepatide (Mounjaro) against semaglutide 1 mg (Ozempic's mid dose) in type 2 diabetes: tirzepatide reduced A1C more at every dose and produced 1.9–5.5 kg more weight loss. Note it compared against 1 mg, not Ozempic's 2 mg maximum.
KEEP EXPLORING
Go further with GLP AI.
Track it once. Understand it forever.
Whichever medication wins, GLP AI tracks it — free to start.